Marksans Pharma Ltd: Stock Analysis & Fundamentals

Updated this week

Marksans Pharma Ltd (Pharma - Formulators) — fundamental analysis, earnings data, and key metrics. PE: 20.5. ROE: 16.8%. This stock is not currently in the Nifty 500 momentum outperformers list.

What's Happening

🌐FII stake decreased 4.4% this quarter

🏛️DII accumulation — stake up 1.2%

Key Numbers

Current Price

₹163

Dividend Yield

0.49%

Market Cap

7.4K Cr

Valuation

N/A

Other Top Pharma - Formulators Stocks Beating Nifty 500

Sun Pharmaceutical Industries Ltd

Strong • 4w streak

+15.9%

Torrent Pharmaceuticals Ltd

Average • 12w streak

+23.4%

Dr Reddys Laboratories Ltd

Zydus Lifesciences Ltd

Weak

+10.0%

← Back to Pharma - Formulators Dashboard

Frequently Asked Questions: Marksans Pharma Ltd

Based on publicly available financial data. This is educational research, not investment advice.

What were Marksans Pharma Ltd's latest quarterly results?

Marksans Pharma Ltd's latest quarterly results (Dec 2025) show

PAT Growth YoY: +8.6%
Revenue Growth YoY: +10.6%
Operating Margin: 21.0%

What is Marksans Pharma Ltd's current PE ratio?

Marksans Pharma Ltd's current PE ratio is 20.5x.

Current PE: 20.5x
Market Cap: 7.4K Cr
Dividend Yield: 0.49%

What is Marksans Pharma Ltd's price-to-book ratio?

Marksans Pharma Ltd's price-to-book ratio is 2.8x.

Price-to-Book (P/B): 2.8x
Book Value per Share: ₹59
Current Price: ₹163

Is Marksans Pharma Ltd a fundamentally strong company?

Marksans Pharma Ltd's fundamental strength based on key financial ratios

Return on Capital (ROCE): 20.0%

Is Marksans Pharma Ltd debt free?

Marksans Pharma Ltd has a debt-to-equity ratio of N/A.

Total Debt: ₹322 Cr

What is Marksans Pharma Ltd's return on equity (ROE) and ROCE?

Marksans Pharma Ltd's return ratios over recent years

FY2023: ROCE 22.0%
FY2024: ROCE 21.0%
FY2025: ROCE 20.0%

Is Marksans Pharma Ltd's cash flow positive?

Marksans Pharma Ltd's operating cash flow is positive (FY2025).

Cash from Operations (CFO): ₹207 Cr
Free Cash Flow (FCF): ₹158 Cr
CFO/PAT Ratio: 54% (adequate)

What is Marksans Pharma Ltd's dividend yield?

Marksans Pharma Ltd's current dividend yield is 0.49%.

Dividend Yield: 0.49%
Current Price: ₹163

Who holds Marksans Pharma Ltd shares — promoters, FII, DII?

Marksans Pharma Ltd's shareholding pattern (Dec 2025)

Promoters: 43.9%
FII (Foreign): 8.1%
DII (Domestic): 5.9%
Public: 42.1%

Is promoter holding increasing or decreasing in Marksans Pharma Ltd?

Marksans Pharma Ltd's promoter holding has remained stable recently.

Current Promoter Holding: 43.9% (Dec 2025)
Previous Quarter: 43.9% (Sep 2025)
Change: 0.00% (stable)

Is Marksans Pharma Ltd a new momentum entry or an established outperformer?

Marksans Pharma Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.

Is Marksans Pharma Ltd worth studying for long term investment?

Based on quantitative research signals, here is why Marksans Pharma Ltd may be worth studying

Cash flow is positive — CFO ₹207 Cr

What is the investment thesis for Marksans Pharma Ltd?

Marksans Pharma Ltd investment thesis summary:

What is the future outlook for Marksans Pharma Ltd?

Marksans Pharma Ltd's forward outlook based on current data signals

Insufficient data for a forward assessment — monitoring for more signals

The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.